Keywords: dosing, starts, topotarget/curagens, ph, ib, trial, pxd101
Dosing starts in TopoTarget/CuraGens' Ph Ib trial of PXD101
Article | 19 September 2005
Danish drugmaker TopoTarget and New Haven, Conneticut, USA-based CuraGen have initiated patient dosing in a Phase Ib open-label, multicenter clinical ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
